Study on the evaluation of the therapeutic effect of Yiqi Huoxue formula combined with antiviral therapy on patients with hepatitis B-related liver fibrosis using the oligosaccharide chain test
10.3760/cma.j.cn501113-20250310-00083
- VernacularTitle:寡糖链检测评估益气活血方联合抗病毒治疗乙型肝炎相关肝纤维化患者的疗效
- Author:
Yaoyao MAO
1
;
Jiaming ZHANG
;
Peizhen LYU
;
Li KONG
;
Na FU
;
Suxian ZHAO
;
Qian WU
;
Cuiying CHEN
;
Yuemin NAN
Author Information
1. 河北医科大学，石家庄 050051
- Publication Type:Journal Article
- Keywords:
Chronic hepatitis B;
Liver fibrosis;
Yiqi Huoxue decoction;
Traditional Chinese medicine;
Nucleos(t)ide analogues;
N-glycan biomarkers;
Glycan test
- From:
Chinese Journal of Hepatology
2025;33(9):880-888
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the impact of the Yiqi Huoxue formula combined with nucleos(t)ide analogs (NAs) antiviral therapy on the serum N-glycan abundance in patients with hepatitis B-related liver fibrosis so as to clarify the application value of the oligosaccharide chain test (GT) for dynamic monitoring of the liver fibrosis progression.Methods:Sixty-two cases diagnosed with chronic hepatitis B at the Department of Hepatology, the Third Hospital of Hebei Medical University, between January 2020 and December 2022 were enrolled and divided into a Yiqi Huoxue Formula (YQHX) combined with NAs group and an NAs monotherapy group ( n=31), with 31 cases in each group for a total of 96 weeks of follow-up. Patient's basic clinical characteristics and liver stiffness measurement (LSM) were collected. GT was used simultaneously to detect the serum N-glycan profile and abundance changes. The nonparametric Mann-Whitney U test was used to compare the differences between the two groups. Enumeration data were expressed as number of cases and percentages (%). The χ2 test was used to compare constituent ratios between two or more groups. Correlation analysis was performed using the Spearman method, with P<0.05 considered statistically significant. Results:The proportion of patients was significantly higher in the YQHX combined with NAs group than the NAs monotherapy group [61.29% (19/31) vs. 9.68% (3/31), P<0.05] with no progression in liver fibrosis staging following 96 weeks of follow-up. The abundance of the N-glycan marker peak 8 [triantennary N-glycan (NA3)] had resulted in significant change for liver fibrosis improvements ( P<0.05), which predicts liver fibrosis progression and reversal in populations sensitive to traditional Chinese medicine. Conclusion:The combined application of Yiqi Huoxue formula and NAs can significantly promote the improvement rate of hepatitis B-related liver fibrosis. Serum N-glycan peak 8 may serve as a potential biomarker for monitoring the reversal of hepatitis B-related liver fibrosis.
